SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 124 filers reported holding SAGE THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is 2.96 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $907,105 | -51.0% | 44,077 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $1,849,470 | 0.0% | 44,077 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,849,470 | +15.2% | 44,077 | +4.7% | 0.00% | 0.0% |
| Q4 2022 | $1,605,389 | -99.9% | 42,092 | +5.7% | 0.00% | 0.0% |
| Q3 2022 | $1,558,724,000 | -7.3% | 39,804 | -23.6% | 0.00% | 0.0% |
| Q2 2022 | $1,681,764,000 | -31.5% | 52,067 | -29.8% | 0.00% | 0.0% |
| Q1 2022 | $2,453,405,000 | -63.4% | 74,121 | -52.9% | 0.00% | -66.7% |
| Q4 2021 | $6,697,371,000 | -4.4% | 157,437 | -0.4% | 0.00% | 0.0% |
| Q3 2021 | $7,006,830,000 | -21.8% | 158,132 | +0.2% | 0.00% | -25.0% |
| Q2 2021 | $8,961,096,000 | -39.4% | 157,738 | -20.2% | 0.00% | -42.9% |
| Q1 2021 | $14,792,906,000 | -58.2% | 197,634 | -51.7% | 0.01% | -58.8% |
| Q4 2020 | $35,365,287,000 | +29.9% | 408,800 | -8.2% | 0.02% | +13.3% |
| Q3 2020 | $27,221,319,000 | +48.5% | 445,375 | +1.0% | 0.02% | +36.4% |
| Q2 2020 | $18,330,376,000 | +147.4% | 440,846 | +70.9% | 0.01% | +120.0% |
| Q1 2020 | $7,408,037,000 | -63.4% | 257,940 | -7.9% | 0.01% | -58.3% |
| Q4 2019 | $20,217,460,000 | -21.3% | 280,059 | +52.9% | 0.01% | -29.4% |
| Q3 2019 | $25,701,829,000 | -36.8% | 183,205 | -17.6% | 0.02% | -41.4% |
| Q2 2019 | $40,692,668,000 | +26.9% | 222,255 | +10.2% | 0.03% | +20.8% |
| Q1 2019 | $32,073,706,000 | +78.7% | 201,658 | +7.6% | 0.02% | +60.0% |
| Q4 2018 | $17,947,023,000 | -29.9% | 187,358 | +3.4% | 0.02% | -21.1% |
| Q3 2018 | $25,584,047,000 | -7.6% | 181,126 | +2.4% | 0.02% | -9.5% |
| Q2 2018 | $27,690,313,000 | -1.4% | 176,901 | +1.4% | 0.02% | -4.5% |
| Q1 2018 | $28,093,347,000 | -2.9% | 174,417 | -0.7% | 0.02% | -12.0% |
| Q4 2017 | $28,928,018,000 | +98.4% | 175,630 | -25.0% | 0.02% | +92.3% |
| Q3 2017 | $14,579,820,000 | -18.2% | 234,026 | +4.6% | 0.01% | -23.5% |
| Q2 2017 | $17,818,893,000 | +7.6% | 223,743 | -4.0% | 0.02% | 0.0% |
| Q1 2017 | $16,565,138,000 | +84771.1% | 233,082 | -39.0% | 0.02% | -22.7% |
| Q4 2016 | $19,518,000 | +8.6% | 382,249 | -2.1% | 0.02% | +15.8% |
| Q3 2016 | $17,978,000 | +80.2% | 390,406 | +17.9% | 0.02% | +72.7% |
| Q2 2016 | $9,974,000 | +249.6% | 331,056 | +272.0% | 0.01% | +266.7% |
| Q1 2016 | $2,853,000 | -47.4% | 88,992 | -4.3% | 0.00% | -50.0% |
| Q4 2015 | $5,422,000 | +146.0% | 92,991 | +78.5% | 0.01% | +200.0% |
| Q3 2015 | $2,204,000 | -41.0% | 52,087 | +1.8% | 0.00% | -50.0% |
| Q2 2015 | $3,736,000 | +54.6% | 51,171 | +6.4% | 0.00% | +100.0% |
| Q1 2015 | $2,416,000 | +33.9% | 48,100 | -2.4% | 0.00% | 0.0% |
| Q4 2014 | $1,804,000 | +52.4% | 49,300 | +31.1% | 0.00% | +100.0% |
| Q3 2014 | $1,184,000 | – | 37,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |